Bevacizumab therapy for macular edema in central retinal vein occlusion: Long-term results

Abstract

Background:There is no proven effective treatment for vision loss in central retinal vein occlusion (CRVO). Bevacizumab has been reported in small series with limited follow-up, to have a positive effect in reducing cystoid macular edema (CME) and improving vision in CRVO.Purpose:To report long-term results with the use of bevacizumab in CRVO.Materials and Methods:Prospective interventional case series included 15 patients, serially evaluated with best corrected visual acuity (BCVA), optical coherence tomography (OCT), fluorescein angiography, and tonometry. Results were statistically analyzed.Results:Mean follow-up was 12 ± 3.6 months (range, 6–18 months); mean number of injections was 2.2 (range, 1–4) per patient. Statistically significant reduction of macular thickness (P < 0.001) was seen at six weeks (mean, 346 μ); three months (mean, 353 μ); six months (mean, 348 μ); and final follow-up (mean, 342 μ). Significant BCVA improvement was seen at six weeks (mean, 0.27 logMAR), three months (mean, 0.3 logMAR), three months (0.15 logMAR), and final follow-up (mean, 0.21 logMAR) (P = 0.009). Also, 73.3% patients had BCVA improvement at the last follow-up.Conclusion:Intravitreal bevacizumab is an effective treatment option for CME in CRVO patients. Reinjections at appropriate timing, based on the OCT findings, are important for better visual outcome.

A comparative study of different concentrations of topical bevacizumab on the recurrence rate of excised primary pterygium: a short-term follow-up study

“…Among them, bevacizumab along with mitomycin C is regarded as a prominent postoperative adjuvant therapy for pterygium. Apart from pterygium, bevacizumab has also been used to treat a variety of other ophthalmic disorders, including central retinal vein occlusion [20], diabetic retinopathy [21], neovascular age-related macular degeneration [22], neovascular glaucoma [23], and corneal neovascularization [24]. Subconjunctival injection, intravitreal injection, and topical administration are three main routes which have been used in these treatments to deliver bevacizumab to the target tissue.…”

The ABCs of RVO: A review of retinal venous occlusion

“…Prompt resolution of macular oedema is desirable given that permanent photoreceptor damage can occur within three months. 37 Such resolution does not lead to a linear improvement in VA. In the case of central RVO, patients with initial VA of 6/12 or better retain that in 65 per cent of cases and 90 per cent remain better than 6/60.…”

“…Prompt resolution of macular oedema is desirable given that permanent photoreceptor damage can occur within three months . Such resolution does not lead to a linear improvement in VA.…”

63 Short term results of intra-vitreal bevacizumab for the treatment of macular edema secondary to retinal vein occlusion

“…Various studies have been published regarding the effectiveness of triamcinolone but its use is complicated by the significant side effects of raised intraocular pressure and cataract (Chen et al, 2006). In recent years, the use of intra-vitreal anti-vascular endothelial growth factor (VEGF) agents, like Bevacizumab (Genentech, USA), have been in increasing use with better results in ME following RVO (Abegg et al, 2008;Badala, 2008;Beutel et al, 2010;Gutièrrez et al, 2008;Fish, 2008;Hung et al, 2001;Iturralde et al, 2006;Kriechbaum et al, 2008;Manayath et al, 2009;Rensch et al, 2009;Pai et al, 2007).…”